Indaptus Therapeutics, Inc. (INDP)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.0800 |
| Open | 2.1800 |
| Bid | 2.2000 x 1000 |
| Ask | 2.5000 x 1000 |
| Day's Range | 2.1300 - 2.2100 |
| 52 Week Range | 1.2500 - 4.0800 |
| Volume | |
| Avg. Volume | 17,200 |
| Market Cap | 18.482M |
| Beta (5Y Monthly) | 1.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8000 |
| Earnings Date | Feb 26, 2024 - Mar 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for INDP
Related Research
- Indaptus Therapeutics, Inc.Daily – Vickers Top Insider Picks for 11/20/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat18 days agoArgus Research
GlobeNewswireIndaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. “We continue to be encouraged by early results from our first cohort of patients in the INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors. As we recently reported and presented at the Society for Immunology in Cancer (SITC) conference, all four first
- GlobeNewswire
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study
Poster presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer Showed Favorable Safety Profile and Achievement of Stable Disease in All Four Patients in First Cohort.NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate a stabilized package of immune agonists to activate both innate (immediate) and adaptive (learned) cellular im
- GlobeNewswire
Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
Poster to be presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer on November 4, 2023 NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announces it will be presenting interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20. The interim data, released today in abstract form, demonstrated that as of August 31, 2023, each of the first cohort participants experienced transient activa
